Imaging of Solid Tumors Using DLL3 SPECT

PRIMARY OBJECTIVE: 1\) Determine the feasibility of detecting tumor uptake using 111In-ABD147. SECONDARY OBJECTIVE: 1\) Safety of 111In-ABD147. EXPLORATORY OBJECTIVES: 1. Correlation of 111In-ABD147 uptake with DLL3 expression determined by immunohistochemistry. 2. Compare 111In-ABD147 scan results to archival Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) images when available. OUTLINE: Participants will be assigned to cohorts based on solid tumor diagnosis. All participants will receive 1 dose of study drug followed by single-photon emission computed tomography (SPECT)/Computerized tomography (CT) imaging. Repeat administration of 111In-ABD147 and SPECT/CT imaging may be performed. Participants will be followed for up to 7 days after last dose for safety.